logo
Inconsistent e-scooter regulations across the country are putting riders and pedestrians at risk

Inconsistent e-scooter regulations across the country are putting riders and pedestrians at risk

At 16, Jasmine Flowers suffered a traumatic brain injury after falling off an e-scooter – an accident she admits was her own fault.
She reached a speed of 28kph while riding her friend's privately-owned device on Queensland's Sunshine Coast when the e-scooter tipped over and she fell.
"It's just black from there," she said.
Jasmine, who was wearing a helmet at the time of the crash, was rushed to hospital and then flown to Brisbane where she was in a coma for several days.
She remained in hospital for a month, and seven months later, still visits regularly for check-ups.
Her father, Gary Flowers, will never forget the moment he saw his daughter after the accident.
He recalled Jasmine covered in blood, crying, writhing in pain, shivering from the cold and vomiting from the trauma.
"It's been an emotional rollercoaster," Mr Flowers said.
The impact of Jasmine's head hitting the bitumen caused her brain to shift inside her skull, resulting in a bleed on the opposite side.
She was left deaf in one ear, unable to fully close her eye and temporarily paralysed in the face.
Jasmine, now 17, still lives with memory loss, brain fog, impulsivity and confusion – and acknowledges the risk she took.
"It was my fault," she admitted.
Jasmine is one of thousands of young Australians who have been injured while riding e-scooters or e-bikes.
Since 2018, Queensland hospitals have recorded almost 6,300 emergency department presentations related to e-scooter crashes.
According to the Jamieson Trauma Institute's Kirsten Vallmuur, nearly 1,100 of those were children under 16 and almost 500 were children under 12.
"Around a third of the patients are saying they were speeding over the 25kph speed limit," she said.
Riding without a helmet or under the influence of alcohol are two of the other key factors in e-scooter crashes not just in Queensland, but across the country.
However, tracking national trends is difficult and researchers have had to rely on individual data-gathering projects to obtain statistics.
"Hospital systems aren't equipped to collect that data in a responsive way," Professor Vallmuur said.
"Even though the collection of data is not systematic [nationally], the kinds of patterns that are coming out [are] quite systematic."
Part of the problem lies in inconsistent regulation, with rules for e-scooters and e-bikes different across Australian jurisdictions.
In Queensland, private e-scooters are legal and can be ridden on footpaths, while in New South Wales, private ownership is banned.
Speed limits also differ.
Some jurisdictions allow up to 25kph while others cap them at 15kph.
Even what qualifies as a legal e-bike differs.
Some states allow throttle-assist bikes, where riders don't need to pedal. Others allow only pedal-assist models.
Narelle Haworth from Queensland's Motor Accident Insurance Commission said differing rules around the country had opened the door to non-compliant and potentially dangerous devices being imported and used.
"[There is] very little checking at the border," she said.
"There's very little need for compliance with the rules that we have here in Australia … so you can import and buy something online that is going to be illegal in the state where you live."
Australia's federal transport department told the ABC states and territories are responsible for e-scooter and e-bike regulation.
"It's clear there is considerable community concern and risk presented by the increasing number of these devices," a spokesperson said.
"That's why the Australian government is continuing to work with the states and territories to explore the risks and opportunities they, as well as personal mobility devices more broadly, present — and identify appropriate risk management strategies."
Queensland and Western Australia are both undertaking public inquiries into e-device use. New South Wales recently concluded a similar inquiry.
Queensland's hearings began last week after the inquiry received more than 1,000 public submissions.
Among those calling for change is 25-year-old Townsville resident Tristan Bowers who loves to walk his guide dog Andy along the city's beachfront promenade – The Strand.
Mr Bowen, who sees only shadows due to optic nerve hypoplasia, said e-scooter and e-bike traffic had turned the 3.5m wide footpath into an obstacle course.
"It's never really possible to get out of the way, so we have to rely on them to get out of [our] way."
Mr Bowen said he didn't want to see the devices banned, but would like to see tighter rules to reduce risk.
"I would like to see speed restrictions and something to make them louder, so when they go past, they're easier to hear," he said.
Professor Haworth, who also works with the Queensland University of Technology Road Safety Research Collaboration, said Australia could learn from overseas jurisdictions.
She pointed to the UK where rental e-scooter riders must have a drivers licence and people must be aged over 14 to ride pedal-assist e-bikes.
"People already know the road rules because they already have a drivers licence and it also puts in a minimum age that is probably at an appropriate level," she said.
For Jasmine, her mission now is to warn others. She speaks to her peers about the risks and wants tighter laws to protect young riders.
Her father agrees — and he's taken his campaign to politicians, calling for changes including full-face helmets, reduced speed limits and education in schools.
He also wants teenagers to complete a safety course before being allowed to ride an e-device.
"No one should have to go through that kind of pain," Jasmine said.
"It was like a fever dream. It was the worst months of my life. I hated every single bit of it.
"Treat it the way you treat a car. Those same laws."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX Health Quarterly Wrap: Neurizon turns up the dial on ALS drug progress
ASX Health Quarterly Wrap: Neurizon turns up the dial on ALS drug progress

News.com.au

time35 minutes ago

  • News.com.au

ASX Health Quarterly Wrap: Neurizon turns up the dial on ALS drug progress

The latest quarterly reporting season is underway, with investors tuning in to see how ASX-listed companies performed during the final months of FY25, and importantly what signals they're sending for the year ahead. Quarterlies offers a crucial opportunity to gauge business momentum and future prospects, particularly for the healthcare sector. After years of underperformance despite solid fundamentals, healthcare has been one of the market's long-suffering segments. While the broader market rose 10%, the ASX healthcare sector decline 4% in FY25. However, recent gains suggest the sector's fortunes may be shifting. The S&P/ASX 200 Health Care Index (ASX:XHJ) surged 5.4% last week, building on a 5% jump the week before and is up so far this week with optimising growing of a rotation back into healthcare stocks. Neurizon advanced its development pathway for its lead drug candidate NUZ-001 during the quarter, achieving several manufacturing, preclinical, clinical, and regulatory milestones. These included development of a liquid formulation of NUZ-001 and promising interim results in the 12-month open label extension (OLE) study in Amyotrophic Lateral Sclerosis (ALS). Neurizon completed a series of foundational studies during the quarter, which deepen the company's "mechanistic understanding of NUZ-001, highlight its differentiated pharmacology, and support its expansion as a platform therapeutic beyond ALS". During the quarter Neurizon made key appointments to its executive team bolstering expertise in finance, preclinical and clinical development as well regulatory strategy to position the company for its next phase of growth, drug development and commercialisation. The company also expanded its global presence and strengthened its engagement with key stakeholders in ALS and neurodegenerative disease through active participation in leading scientific, industry and community events. Neurizon said achievements during the June quarter provided the catalyst for crucial milestones post quarter-end, including an exclusive global license agreement with NYSE-listed Elanco Animal Health Incorporated for monepantel (NUZ-001). Post-quarter end the biotech received positive written feedback from the US Food & Drug Administration (FDA) on its strategy to resolve the clinical hold for NUZ-001. The company has submitted a comprehensive Clinical Hold Complete Response (CHCR) to the regulator requesting the clinical hold to be lifted, paving the way to advance its investigational new drug application (IND) and entry into the HEALEY ALS platform trial in the December quarter. Neurizon has also announced it has executed a loan agreement for $1.5m with specialist R&D financing firm Radium Capital, which is secured against a small portion of its expected 2025 R&D tax rebate. The loan provides provides non-dilutive funding on top of Neurizon's existing cash balance of $4,161,000 at the end of June to ensure the company can maintain its pipeline of work in advance of receiving this year's R&D tax rebate. Arovella Therapeutics (ASX:ALA) A biotech focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, Arovella continued to progress its lead product, ALA-101, towards a first-in-human clinical trial and to expand its platform into solid tumours during the quarter. During the quarter, Arovella expanded its management team in readiness for its first-in-human phase I clinical trial for ALA-101 with the appointment of clinical operations leader Jacqui Cumming as senior director, clinical development. The company entered into an exclusive option to licence multiple patent families from Baylor College of Medicine to expand use and improve the performance of its iNKT cell platform. Arovella also set up its own research laboratory within the Jumar Bioincubator, with the new facility enabling Arovella to speed up its research output as it expands its solid tumour programs and continues building on its IP portfolio. At the end of the quarter, Arovella announced that Dr Thomas Duthy would retire as a non-executive director and chairman with current non-executive director Dr Elizabeth Stoner serving as interim chair. Arovella's CEO and managing director Dr Michael Baker said it was a productive quarter, including preparing an IND submission for the FDA. "We made significant progress preparing for submission of our IND application, and we believe we are positioning the company for the best chance of success with the FDA," he said. The company finished Q4 FY25 with cash of $20.9m, which is expected to fund the company through to completion of patient enrolment for the phase I clinical trial for ALA-101. The funding will also support the advancement of its solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). During the quarter Perth-based medtech Singular Health signed a commercial pilot agreement valued at US$1.3m (~A$2m). with major managed service organisation (MSO) in the US Provider Network Solutions (PNS), which manages care for more than 3.7 million people. The contract marks transition to phase three of the company's multi-phase engagement with PNS and involves co-development of a pilot program where 1,000 of Singular Health's 3DICOM MD licenses will be distributed to primary care providers. Following quarter close Singular Health announced a six-month collaboration with radiologist and founder of Life Radiology in Doral, Florida Dr Alex Alonso, who will serve as a strategic advisor and radiology architect for the PNS pilot, offering technical insight into US standards and workflows. Singular Health also progressed multiple commercial discussions across the US education and healthcare sectors during the quarter with proposals requested by private and public institutions. The company commissioned an independent report by Signify Research to quantify the US market opportunity. The findings show a total addressable market exceeding US$19 billion, with ~1.3 million primary care physicians in the US and each representing an average licence opportunity of US$800 per year. Singular Health continued to pursue strategic opportunities in Australia aimed at improving access to medical imaging data and supporting clinical training, including a proof-of-concept integration proposal submitted to government departments to address inefficiencies in retrieving imaging data across disconnected PACS environments. During the quarter, a capital raise of $8m was completed at an issue price of 35 cents per share, led by the Wallabi Group. The raise included participation from several institutional and high-net-worth investors, with further investment from PNS and Marin and Sons. On the regulatory front, the company successfully completed its ISO 13485 re-certification and confirmed SOC 2 Type 2 and HIPAA formal certification and also progressed technical development. The company closed out quarter with $13.7m cash and no debt. Nerve-repair company ReNerve reported quarter sales revenue rose by 25% to $94,000 and contributed to cumulative FY25 sales of $271,000, up 53% on the previous year. During the quarter ReNerve entered a partnership with Berkeley Biologics to develop two new product ranges, strengthening its commercial portfolio in the regenerative tissue and biologics sector. Launch of the first new product ranges under the ReNerve brand are expected in Q3 CY25 and second by end of CY25. The company received marketing approvals for its NervAlign Nerve Cuff in Bahrain, marking the first regulatory approval secured through its exclusive distribution agreement with Union MediScience B.S.C. ReNerve and Union MediScience are now progressing with commercial rollout processes for the NervAlign Nerve Cuff product in the country, with early clinical cases and data gathered now anticipated to support future regulatory submissions in additional Middle East and North Africa (MENA)jurisdictions. In April ReNerve signed a deal with NetCentrix Ventures to pursue regulatory approval and commercialisation of the NervAlign Nerve Cuff in India. The Indian nerve repair market is valued at ~US$115 million and forecast to exceed US$270 million by 2030. ReNerve's net cash position at the end of the quarter was $4.75 m. Imagion Biosystems (ASX:IBX) Focus on progressing MagSense HER2 breast cancer imaging agent program during quarter Working towards filing IND application to US FDA in Q3 FY25 for phase II trial Preparations underway for manufacturing of MagSense HER2 drug for use in trial The majority of Imagion's activities in the quarter focused on progressing its MagSense HER2 breast cancer imaging agent program towards filing an IND application to the US FDA for its phase II clinical trial including: Submission of a pre-IND briefing document to the FDA Preparations for manufacturing of the MagSense HER2 drug for use in phase II trial Surgical oncologist at University of Oklahoma Health Sciences College of Medicine Dr William Dooley appointed principal investigator Subsequent to the quarter close Imagion received positive written formal feedback from the FDA regarding the pre-IND briefing documents submitted. The IBX clinical team then held a meeting with senior FDA advisors to review the IND submission, which could be filed as early as Q3 CY25. Start of the phase II trial is subject to IND approval by the FDA, with a response expected in Q4 CY25. During the June quarter, Imagion entered into a master service agreement with Biosensis Ltd, providing the company with the ability to keep its operating costs low by not having to maintain an R&D facility or personnel, while still having access to new nanoparticle formulations for future research programs. The two companies previously entered a licensing agreement in 2024, allowing Biosensis to use Imagion's proprietary nanoparticle manufacturing methods to supply research markets. During the quarter vice chair of innovation at University Hospitals and an associate professor of radiology at Case Western Reserve University in Cleveland Dr Leonardo Kayat-Bittencourt was appointed clinical advisor for the company's prostate cancer program. Imagion ended the quarter with $883,000 cash, down $826,000 from the prior quarter. Operating cash outflow for the quarter was $818,000, a $141k improvement largely due to lower admin and corporate costs. The company expects reduced outflows next quarter as it focuses on cost control and funding the IND application.

Doubling up: How ASX biotechs are multiplying their impact
Doubling up: How ASX biotechs are multiplying their impact

News.com.au

time35 minutes ago

  • News.com.au

Doubling up: How ASX biotechs are multiplying their impact

ASX companies finding smarter ways to stretch value of existing assets and launch into broader clinical areas LTR Pharma leveraging proven intranasal platform for erectile dysfunction treatment to target non-invasive relief for patients with swallowing difficulties From concussion to Alzheimer's the CogState Cognigram digital cognitive assessment system is used by physicians to monitor brain function As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to find smarter ways to stretch the value of their existing assets. Whether it's repurposing a drug delivery platform, extending the reach of a diagnostic tool or developing next-generation compounds that act on the same biological pathway to treat other conditions, these companies are using proven science as a launchpad into broader clinical territory. The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss. Blockbusters like Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) are now reshaping treatment for obesity and related conditions. It's a compelling demonstration of how one well-validated mechanism of action can be leveraged across multiple disease areas in turn lowering development risk, tapping into existing safety and efficacy data, and accelerating time to market. For ASX healthcare companies navigating tighter capital conditions, similar strategies are proving to be a smart and resourceful way to unlock broader clinical value from their existing platforms. LTR Pharma rises above ED with nasal spray tech targeting broader conditions Developer of a nasal spray treatment for erectile dysfunction (ED), LTR Pharma (ASX:LTP) has turned to a secondary program using its innovative intranasal delivery platform but this time for oesophageal motility disorders (OMD). In May, LTR Pharma announced it had inked a collaborative development agreement with US-based Strategic Drug Solutions (SDS) to develop Oroflow a spray for OMD – a group of conditions that cause impaired swallowing (dysphagia). The program leverages LTR's proven proprietary intranasal delivery platform and foundational work from its Spontan and Roxus ED treatments to target rapid symptom relief for patients with swallowing difficulties, potentially offering a non-invasive alternative to current treatments. Oroflow aims to deliver relief in 10 minutes, bypassing swallowing barriers and offering a compelling althernative to treatments including invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections. LTR Pharma is addressing a $4.5 billion OMD market projected to reach $8.1 bn by 2034 with the company announcing in its latest quarterly report that proof-of-concept testing preparations were underway. LTR Pharma executive chairman Lee Rodne said Oroflow represented an exciting expansion of its nasal spray platform. "For patients with swallowing difficulties, oral medications present obvious challenges for patients," he said. "Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief. Neuren targeting broad set of neurological conditions Neuren Pharmaceuticals (ASX:NEU) is another standout. The company and US partner Acadia was in 2023 granted the first US Food and Drug Administration (FDA) approval for a drug to treat Rett syndrome, a rare neurological disorder mostly affecting girls and emerging in infancy. Trofinetide, marketed as Daybue, is a synthetic analog of part of the hormone insulin-like growth factor 1 (IGF-1), which is a potent regulator of central nervous system development. Neuren is now advancing NNZ-2591, which also targets IGF-1. Building on the scientific foundation of trofinetide, NNZ-2591 is structurally optimised to improve brain penetration, enhance tolerability, and expand therapeutic reach across a broader set of neurodevelopmental conditions. Using a strategy that targets multiple indications from one compound, Neuren aims to accelerate development while reducing R&D expenses. Currently in phase II trials, NNZ-2591 could open new treatment avenues for other underserved neurodevelopmental conditions like Phelan-McDermid, Angelman, and Pitt-Hopkins syndromes. The company is preparing to start a phase III study of NNZ-2591 for its most advanced program Phelin McDermid. It also plans to consult with the FDA this year to establish a clinical path for NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), which results from a baby's brain not getting enough oxygen or blood flow before, or shortly after, birth. "We believe the mechanism of action of NNZ-2591 can be broadly applicable to neurodevelopmental disorders, independent of the genetic origin," CEO Jon Pilcher told Stockhead. "We are striving to be successful in multiple settings, for the benefit of both the impacted families and our shareholders." Tracking cognition from concussion to Alzheimer's From footy fields to neurology clinics, the CogState (ASX:CGS) Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of brain function – including processing speed, attention, visual learning, working memory and executive function. The test can assess cognition at a single point in time or track changes over multiple assessments. You may have heard of it referred to as the Cogstate concussion test in footy coverage. However, Cognigram has since evolved into a widely used tool in healthcare and research. Cogstate is riding a wave of global demand for cognition-related clinical trials, particularly in the race to treat Alzheimer's disease and related dementias. The company recently upgraded its financial guidance for FY25, reflecting strong performance and improved outlook across key financial metrics. Full-year profit before tax is forecast to be in the range of $12-14m, an improvement of 69% to 97% on FY24. "We are now using Cognigram, which is the same cognitive assessment used to assess AFL footballers for concussion, to prescreen for clinical trials in the earlier stages of Alzheimer's," CEO Brad O'Connor told Stockhead. "We have a contract with a large pharmaceutical company screening for 20,000 patients in the community to find those that might be appropriate to include in their very early stage Alzheimer's trials.

A dead 'doctor', cancer and 'woo woo': Inside Australia's ozone therapy industry
A dead 'doctor', cancer and 'woo woo': Inside Australia's ozone therapy industry

ABC News

timean hour ago

  • ABC News

A dead 'doctor', cancer and 'woo woo': Inside Australia's ozone therapy industry

Cara does not consider herself to be "woo woo" but when she started experiencing unexplained health symptoms, she became curious about alternative medicine. She booked in at The Ozone Clinic in Sydney's Castle Hill after seeing positive reviews online, hoping it would cure her brain fog and body aches. Stepping inside, Cara, who does not wish to use her last name, remembers thinking something was amiss. "They put me on a bed and spun me upside down and were tapping random parts of my body," she recalled. The practitioner presented her with a booklet with red markings — red indicating her level of supposed disease was high. "Then they said we've got a solution for you. It happens to be ozone therapy for $1,500 a pop,'" she said. Ozone therapy is an alternative therapy that involves administering ozone gas into a patient's body either intravenously, through inhalation, or via the rectum and vagina. It is considered to be an experimental and sometimes risky therapy and is not approved for medical use by the Therapeutic Goods Administration (TGA) in Australia. The clinic Cara attended was run by Ukrainian-born Edward Dulitsky, who marketed himself as a holistic doctor despite not being registered as a doctor in Australia. An online profile lists him as a "neurologist" and "health consultant" with a PhD in science and ozone therapy from Russia. His website, which has been deleted, states he treated thousands of patients with ozone therapy for a variety of conditions, including chronic fatigue, Lyme-like disease and cancer rehabilitation. Cara remembers getting a "dodgy vibe" from Mr Dulitsky. Mr Dulitsky died in suspicious circumstances in a hotel room in Russia in 2023 while on a business trip. His wife believes he may have been murdered. Following Mr Dulitsky's death, his wife resumed operations of the business before it was shut down. In August 2024, a year after his death, the Sydney clinic was raided by officers from the NSW Health Care Complaints Commission (HCCC), who found a range of drugs imported from Russia bound in gaffer tape that looked like they had been strapped to an item — or person — and smuggled into the country. The clinic was slapped with an interim prohibition order and banned from delivering ozone therapy for medical purposes while the commission investigated a complaint from a patient. If you have any information about a story, contact Victoria Pengilley. Mr Dulitsky's wife, who did not want to be named, said she believed the patient's complaint was bogus, though the HCCC said substantial evidence was gathered during their investigation. The clinic attracted patients from far and wide, including Blue Wiggle Anthony Field, who was pictured receiving ozone therapy in a now deleted Facebook post from July 2021. "Anthony Field, the Blue Wiggle, has brought his friend to The Ozone Clinic for alternative cancer support treatment — the same place Anthony himself has been successfully treated for his own Lyme-like illness," the post said. His friend pictured in the photo was military veteran Brendan Nikolajew, who died after battling cancer in 2021. The ABC is not suggesting Mr Nikolajew received ozone therapy or that it contributed or led to his death. Cara also remembers seeing Mr Field in the waiting room while waiting for her session with Mr Dulitsky. In a statement, a Wiggles spokesperson said Mr Field sought help from the clinic in 2021 after a period of serious and ongoing health challenges. "Like many people facing complex health issues, he explored a range of options in good faith," the spokesperson said. "Anthony is not a medical professional and has always relied on the guidance of qualified and registered practitioners. "He would never knowingly be involved in, or support, unregulated medical practices." Ozone gas is generated using a machine that applies electricity to convert regular oxygen (O₂) into ozone (O₃). At Mr Dulitsky's clinic, the form of ozone therapy used reportedly involves drawing a small amount of the patient's blood, mixing it with ozone, and then reinfusing it into the body — a process known as autohemotherapy. There is limited peer-reviewed evidence or clinical trial data supporting the effectiveness of ozone therapy in treating chronic health conditions. The therapy also carries potential risks, including serious or even fatal side effects. Between 1975 and 1983, six people in Germany died after developing gas embolisms following improper intravenous administration of ozone gas. Other reported complications include septic shock and respiratory issues linked to ozone inhalation. The Castle Hill clinic is one of two facilities providing ozone therapy in Sydney to be shut down by the NSW HCCC following patient complaints. The Ozone Healing Clinic in Penrith Westfield Shopping Centre was issued with a prohibition order in April after a patient contracted sepsis. Linh Tuan Phan, a non-registered practitioner who worked at the Penrith clinic, was also accused of maintaining poor hygiene levels and obtaining an illegal prescription for a blood thinner to use on patients. Efforts to contact Mr Phan were unsuccessful. HCCC Commissioner John Tansey said poor hygiene was a common sight for officers investigating clinics. "In some of the facilities they were keeping equipment and drugs in the same fridge in the staff kitchen as people were keeping their lunch," Mr Tansey said. There is no firm data for how many Australians use ozone therapy as it is not recognised by the complementary medicine peak body. But online, hundreds of patients have reported turning to buying ozone machines from overseas, and oxygen gas bottles from Bunnings to perform the treatment on themselves at home. "That's absolutely scary to be honest," Mr Tansey said. The HCCC believes the number of complaints is under-reported. "We also have evidence that some practitioners will actively discourage people to not complain. They might offer to refund the money," Mr Tansey said. Cara was eventually diagnosed with a histamine intolerance but spent years thinking she had Lyme disease, which is not recognised as a locally acquired disease in Australia. She believes ozone clinics are preying on vulnerable people who feel forgotten by the medical system. "I was very unwell and went through all the traditional avenues of GPs and specialists, they couldn't find any answers," she said. Louise Stone, an associate professor at the University of Adelaide, who investigates medically unexplained illnesses, said Cara's situation was common among patients who could not be diagnosed. "It's like a cold case mystery in that medicine has edges and our tests will only go so far," Dr Stone said. "To be left without a name for your illness is to be left without a story. "I've seen so many patients who have spent so much money on a treatment that has promised the world, and is actually not evidence-based at all."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store